Successful mobilization and transplantation of filgrastim mobilized hematopoietic stem cells in sickle cell-hemoglobin C disease [2]

Bone Marrow Transplantation

Volumn 37, Issue 11, 2006, Pages 1065-1066

  Kamble, R T ^a   Tin U, C K ^b   Carrum, G ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b TEXAS ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; HEMOGLOBIN S; IFOSFAMIDE; MELPHALAN; MEPREDNISONE; PHOSPHATE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADULT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER STAGING; CASE REPORT; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; EXCHANGE BLOOD TRANSFUSION; EXTERNAL BEAM RADIOTHERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN SC DISEASE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LETTER; LEUKOCYTE COUNT; MALE; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BLOCKING; SALVAGE THERAPY; STEM CELL MOBILIZATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ADULT; EXCHANGE TRANSFUSION, WHOLE BLOOD; FILGRASTIM; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOGLOBIN SC DISEASE; HUMANS; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; TRANSPLANTATION, AUTOLOGOUS;

EID: 33646804895     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705376     Document Type: Letter

References (12)

1. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH et al. Mortality in sickle cell disease - life expectancy and risk factors for early death. N Engl J Med 1994; 330: 1639-1644.
2. Onitilo AA, Lazarchick J, Brunson CY, Frei-Lahr D, Stuart RK. Autologous bone marrow transplantation in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc 2003; 35: 3089-3092.
3. Paydas S. Sickle cell anemia and hematological neoplasias. Leuk Lymphoma 2002; 43: 1431-1434.
4. Stricker RB, Linker CA, Crowley TJ, Embury SH. Hematologic malignancy in sickle cell disease: Report of four cases and review of the literature. Am J Hematol 1986; 21: 223-230.
5. Adler BK, Salzman DE, Carabasi MH, Vaughan WP, Reddy VVB, Prchal JT. Fatal sickle cell crisis after granulocyte colony-stimulating factor administration. Blood 2001; 97: 3313-3314.
6. Wei A, Grigg A. Granulocyte colony-stimulating factor-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/B+ thalassemia. Blood 2001; 97: 3998-3999.
7. Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005; 106: 1867-1874.
8. + cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 1095-1102.
9. Liles WC, Broxmeyer HE, Rodger E, Wood B, Hubel K, Cooper S et al. Mobilization and hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003; 102: 2728-2730.
10. Kang EM, Areman EM, David-Ocampo V, Fitzhugh C, Link ME, Read EJ et al. Mobilization, collection, and processing of peripheral blood stem cells in individuals with sickle cell trait. Blood 2002; 99: 850-855.
11. MacDonald R. Red cell 2, 3-diphosphoglycerate and oxygen affinity. Anaesthesia 1977; 32: 544-553.
12. Raanani P, Levi I, Holzman F, Grotto I, Brok-Simoni F, Avigdor A et al. Engraftment-associated hypophosphatemia - the role of cytokine release and steep leukocyte rise post stem cell transplantation. Bone Marrow Transplant 2001; 27: 311-317.